Immunome Research
Open Access

Immunological Approaches Used in Vaccine Development

Denis Mogilenko^{* *}Correspondence: Denis Mogilenko, Department of Immunogenetics, University of Catania, Catania, Italy, Email:

Author info »

About the Study

Vaccines have played a crucial role in preventing infectious diseases and have significantly contributed to public health worldwide. Immunological approaches to vaccine development involve harnessing the body's immune system to provide protection against specific pathogens. Over the years, researchers have made significant advancements in understanding immune responses and applying this knowledge to develop effective vaccines.

Vaccine development

Live attenuated vaccines contain weakened forms of the pathogen that can replicate within the host but cause minimal or no disease symptoms. These vaccines stimulate both the innate and adaptive immune responses, closely mimicking natural infection. Examples of successful live attenuated vaccines include Measles, Mumps, Rubella (MMR), and yellow fever vaccines. However, the use of live attenuated vaccines presents challenges, such as the potential for reversion to virulence, requiring careful attenuation and safety evaluation.

• Inactivated vaccines consist of whole, inactivated pathogens or their subunits, unable to replicate in the host. These vaccines primarily stimulate the adaptive immune response. Inactivation methods can include heat or chemical treatments. Inactivated vaccines, such as the influenza vaccine and polio vaccine, have been instrumental in disease prevention. However, these vaccines often require adjuvants to enhance immune responses and may necessitate multiple doses or booster shots to maintain protection.

• Subunit vaccines contain purified antigens derived from the pathogen, focusing on key components that induce protective immune responses. These antigens can be proteins, peptides, or polysaccharides. Subunit vaccines offer enhanced safety compared to whole pathogen vaccines and can be produced through recombinant DNA technology. Examples include the hepatitis B vaccine and the Human Papillomavirus (HPV) vaccine. Subunit vaccines often require adjuvants or delivery systems to enhance immunogenicity.

• DNA vaccines involve the direct injection of plasmid DNA encoding antigenic proteins into host cells. These vaccines can induce both humoral and cellular immune responses. DNA vaccines offer advantages such as ease of production, stability, and potential for rapid development against emerging pathogens. However, their effectiveness in humans has been limited, requiring optimization strategies to improve immunogenicity.

• Viral vector vaccines utilize genetically modified viruses as delivery vehicles to express antigenic proteins and stimulate immune responses. The viral vectors can be derived from nonpathogenic viruses, such as adenoviruses or vesicular stomatitis viruses. Notable examples of viral vector vaccines include the Oxford-AstraZeneca COVID-19 vaccine (based on a chimpanzee adenovirus vector) and the Johnson and Johnson COVID-19 vaccine (based on an adenovirus serotype 26 vector). Viral vector vaccines offer potent immune responses, but pre-existing immunity to the vector can limit their effectiveness.

• mRNA vaccines represent a revolutionary approach that emerged in recent years. These vaccines introduce synthetic mRNA encoding the pathogen's antigenic proteins into host cells, which then produce the viral proteins to elicit an immune response. mRNA vaccines gained significant attention during the COVID-19 pandemic, with the Pfizer- BioNTech and Moderna vaccines achieving high efficacy rates. mRNA vaccines offer several advantages, including rapid development, scalability, and flexibility in targeting different pathogens. Ongoing research aims to explore mRNA vaccine platforms for various diseases.

Novel approaches

In addition to the above-mentioned approaches, researchers continue to explore novel immunological strategies. These include Virus-Like Particle (VLP) vaccines, nanoparticle-based vaccines, and mucosal vaccines. VLP vaccines mimic the structure of viruses without the genetic material, stimulating robust immune responses. Nanoparticle-based vaccines utilize nanoparticles as carriers for antigens or adjuvants, enhancing immune recognition. Mucosal vaccines aim to stimulate immune responses at the site of pathogen entry, such as the respiratory or gastrointestinal tract, providing localized protection.

Challenges and future perspectives

While immunological approaches have revolutionized vaccine development, several challenges remain. Adjuvant selection, vaccine stability, and the need for cold chain distribution are among the challenges for vaccine formulations. Moreover, vaccine hesitancy, access, and equity pose significant barriers to achieving global immunization goals. In the future, advancements in computational biology, structural vaccinology, and immunogenomics will contribute to vaccine design and optimization. Personalized vaccines targeting specific genetic variations or cancer antigens hold promise for personalized medicine. Additionally, ongoing research on universal vaccines, capable of providing broad protection against multiple strains or even entire families of pathogens, represents an exciting avenue.